Biotech company Argenica Therapeutics Limited (ASX: AGN), which is developing novel therapeutics to reduce brain tissue death after stroke, has completed the production of its neuroprotective peptide candidate ARG-007 in powder form. The Company is gearing up for its Phase 2 clinical trials, and the final manufacturing of the sterile drug product in vials is
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.